Investors & Media
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat central nervous system (CNS) diseases. Minerva’s proprietary compounds include: MIN-101, which has completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials for insomnia and MDD, respectively; MIN-117, which has completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”
We are committed to providing investors access to current and historical information about Minerva Neurosciences, Inc., including news regarding product development programs, key shareholder updates and financial reports.
Events & Presentations
August 03, 2017 at 8:30 AM EDT August 03, 2017
8:30 AM EDT
June 06, 2017 at 11:00 AM EDT June 06, 2017
11:00 AM EDT